October 26, 2020

Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a blinded, randomized, controlled trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

[conference abstract, not peer-reviewed] Taking a two-week course of hydroxychloroquine did not prevent SARS-CoV-2 infection among household members of people with SARS-CoV-2 in a national, household-randomized trial in the US. Among participants who were SARS-CoV-2 negative at enrollment, there were 46 new infections among participants randomized to hydroxychloroquine (n=381) and 43 in the control participants (n=400)(aHR=0.99, 95% CI 0.64-1.52). There was no difference between groups in symptomatic COVID-19 or adverse event frequency.

Barnabas et al. (Oct 24, 2020). Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a blinded, randomized, controlled trial. https://www.eventscribe.net/2020/IDWeek/fsPopup.asp?Mode=presInfo&PresentationID=798021